Micron Biomedical

California, here we come! Micron Biomedical leadership will be in San Francisco during #JPM25 week to meet with industry leaders, stakeholders and future partners. Our CEO, Steven Damon, our EVP and Head of Technical Operations, Sebastien Henry, and our CFO, Idean M., are looking forward to an exciting and productive week--and still have a few meeting times remaining. Reach out to us here or at info@micronbiomedical.com to schedule a time to meet with the Micron Biomedical leadership team. 

What a year it's been! Take a trip down memory lane with us as we reflect on Micron's highlights and achievements in 2024. We've covered so much ground and gained so much momentum in bringing needle-free vaccines and therapeutics to market, and the future looks brighter than ever. We couldn't have done it without the support of our dedicated team, our investors and funders, and people like you. Thank you for a phenomenal year.

Micron Biomedical is looking forward to kicking off the new year at Biotech Showcase 2025 in San Francisco, California. If you are attending #JPM25 or #BiotechShowcase25, let's make a plan to meet!

Micron Biomedical wishes you a joyous and healthy holiday season!

Sometimes the biggest solutions come in the smallest packages. Micron’s dissolvable microarray technology has the potential to tackle the most pressing challenges to global and local vaccine and therapeutic delivery. With thermostable properties and needle-free administration, Micron’s technology requires no reconstitution, reduces or eliminates the need for a cold chain, produces no sharps waste, and can be administered by a non-clinician or caregiver. Learn more about our technology here: https://lnkd.in/gKqNfqXf

20.5 million children worldwide are missing out on life-saving vaccines, but it doesn’t have to be that way. In much of the world, common barriers to vaccine access like underdeveloped infrastructure, unavailability of a cold chain, and limited healthcare professionals hinder access to vital #vaccines and other #medicines. Micron Biomedical is breaking these barriers to access with needle-free technology that can be self-administered, reduces or eliminates the need for cold storage and transportation, and can be shipped virtually anywhere. Our technology has been successfully used in the Gambia to vaccinate children as young as nine months old against #measles and rubella – demonstrating the promise of eradicating disease in previously hard to reach locations. Learn more about Micron Biomedical here: https://lnkd.in/gTY-g4Ta

Being far from care is a reality for more than 30 million Americans today – limiting their access to health services, treatments, vaccines and prescription medications. But being far from care doesn’t have to mean that life-saving vaccines and therapeutics are out of reach. Micron Biomedical is envisioning a future where previously injectable-only medicines can be sent directly to those who need them, and self-administered at home. With innovative technology that is lightweight, thermostable and needle-free, the future is looking brighter. Learn more about our technology here: https://lnkd.in/gTY-g4Ta

Each year, The Galien Foundation celebrates breakthrough scientific achievements that improve the human condition with some of the industry’s most distinguished and inspiring industry leaders, regulators, and patient advocates. Last month, Micron Biomedical, was honored to be featured among the most innovative and distinguished startups in the world as a finalist for the Prix Galien Best Startup Award. The recognition of Micron Biomedical’s breakthrough technology as a finalist was incredibly meaningful and we thank The Galien Foundation for spotlighting our commitment to making life-changing innovations more accessible. We’re proud to lead the industry in dissolvable microarray technology and we are passionate about making needle-free vaccines and therapeutics for conditions like obesity, pain, infertility and diabetes. Thank you, Galien Foundation, for this red carpet night to remember and for your recognition.   

Dr. Seth Berkley, Micron’s Scientific Advisor to the CEO, is speaking at the 2025 World Vaccine Congress on the crucial topics of threats to public health, emerging diseases and measles eradication goals. Micron Biomedical leads the world in needle-free #measles and rubella vaccinations for children as young as nine months old in areas that have historically faced the highest barriers to vaccine and therapeutic access. We are proud to play a critical role in global goals to eradicate measles and we are excited to hear Dr. Berkley’s expert perspective.